Amgen announces positive top-line results from phase 3 study of Prolia® (denosumab)
Amgen announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. August 29, 2016